X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/polaryx-therapeutics-announces-fda-grants-orphan-drug-designation-for-plx-200-in-gm2-gangliosidoses-301364861.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-krabbe-disease-with-plx-300-301226528.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-krabbe-disease-with-plx-300-301226528.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-niemann-pick-disease-types-a-and-b-with-plx-300-301195771.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-niemann-pick-disease-types-a-and-b-with-plx-300-301195771.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-gm2-gangliosidosis-with-plx-300-301180296.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-gm2-gangliosidosis-with-plx-300-301180296.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-fda-fast-track-designation-to-plx-200-for-the-treatment-of-patients-with-juvenile-neuronal-ceroid-lipofuscinosis-301115070.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-ind-approval-from-the-fda-to-study-plx-200-treatment-for-patients-with-juvenile-neuronal-ceroid-lipofuscinosis-301037012.html
https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-ind-approval-for-plx-200-from-the-fda-for-the-treatment-of-late-infantile-neuronal-ceroid-lipofuscinosis-300989408.html
Market Place
Share 
